{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:17:34Z","timestamp":1768911454989,"version":"3.49.0"},"reference-count":200,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.autrev.2023.103362","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:30:23Z","timestamp":1684863023000},"page":"103362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biologic therapy in large and small vessels vasculitis, and Beh\u00e7et\u2019s disease: Evidence- and practice-based guidance"],"prefix":"10.1016","volume":"22","author":[{"given":"Jo\u00e3o","family":"Ara\u00fajo Correia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gl\u00f3ria","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Matos-Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Delgado","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Campar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Marado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelita","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milene","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103362_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103362_bb0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103362_bb0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0035","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0040","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/13543784.2017.1361928","article-title":"Investigational drugs in systemic vasculitis","volume":"26","author":"Mirouse","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2023.103362_bb0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12016-017-8643-2","article-title":"Unmet needs in the pathogenesis and treatment of vasculitides","volume":"54","author":"Muratore","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2023.103362_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0060","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2023.103362_bb0065","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0070","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0075","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients","volume":"43","author":"R\u00e9gent","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/OPTH.S243203","article-title":"Giant cell arteritis: the experience of two collaborative referral centers and an overview of disease pathogenesis and therapeutic advancements","volume":"14","author":"Dammacco","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.autrev.2023.103362_bb0090","doi-asserted-by":"crossref","first-page":"rkaa017","DOI":"10.1093\/rap\/rkaa017","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2023.103362_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","article-title":"Tocilizumab as an add-on therapy to glucocorticoids during the first 3\u00a0months of treatment of Giant cell arteritis: A prospective study","volume":"57","author":"Samson","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000137","article-title":"Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis","volume":"2","author":"Evans","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103362_bb0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0110","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0115","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/key158","article-title":"Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis","volume":"57","author":"Gloor","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13075-020-02311-y","article-title":"Tocilizumab in treatment-na\u00efve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial","volume":"22","author":"Mekinian","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103362_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0130","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0135","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jbspin.2013.11.008","article-title":"Takayasu arteritis and NYHA III\/IV idiopathic cardiomiopathy: tocilizumab proves effective and safe","volume":"81","author":"Schiavon","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103362_bb0140","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.114.014321","article-title":"Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients","volume":"132","author":"Mekinian","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.autrev.2023.103362_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.autrev.2017.11.026","article-title":"Tocilizumab and refractory Takayasu disease: Four case reports and systematic review","volume":"17","author":"Decker","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103362_bb0150","first-page":"S44","article-title":"Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review","volume":"34","author":"Loricera","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0155","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0160","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.40105","article-title":"Abatacept as adjunctive therapy for the treatment of giant cell arteritis: comment on the article by Langford et al","volume":"69","author":"de Boysson","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 129","key":"10.1016\/j.autrev.2023.103362_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.55563\/clinexprheumatol\/l0hd9v","article-title":"An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis","volume":"39","author":"Rossi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0170","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0175","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0180","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03009742.2015.1060521","article-title":"Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application","volume":"45","author":"Terao","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/14397595.2020.1800560","article-title":"Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab","volume":"31","author":"Gon","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001020","article-title":"Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis","volume":"5","author":"\u00c1gueda","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103362_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001003","article-title":"Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis","volume":"5","author":"Monti","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103362_bb0205","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.reuma.2016.06.003","article-title":"Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases","volume":"13","author":"Vinicki","year":"2017","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.autrev.2023.103362_bb0210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00296-016-3521-4","article-title":"Successful treatment of refractory giant cell arteritis with etanercept","volume":"36","author":"Fujita","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103362_bb0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0220","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0230","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0235","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jjcc.2016.07.009","article-title":"Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment","volume":"69","author":"Ohigashi","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.autrev.2023.103362_bb0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/mr\/roab012","article-title":"Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort","volume":"32","author":"Tomelleri","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115026","article-title":"The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis","volume":"9","author":"Osman","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103362_bb0250","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-007-0684-0","article-title":"The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab","volume":"26","author":"Mayrbaeurl","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0255","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","article-title":"Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis","volume":"64","author":"Bhatia","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0260","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10067-014-2506-5","article-title":"Two Takayasu arteritis patients successfully treated with rituximab","volume":"33","author":"Caltran","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0265","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00296-019-04390-w","article-title":"Refractory Takayasu arteritis successfully treated with rituximab: case-based review","volume":"39","author":"Mutoh","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103362_bb0270","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/rheumatology\/kex249","article-title":"Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature","volume":"57","author":"Pazzola","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0275","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","volume":"81","author":"Ly","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103362_bb0285","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/keab280","article-title":"Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments","volume":"61","author":"Deshayes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0290","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/annrheumdis-2019-216606","article-title":"Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis","volume":"79","author":"Kuwabara","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0295","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kez580","article-title":"A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib","volume":"59","author":"Sato","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2023.103362_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217894","article-title":"Comment on: \u2018Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis\u2019 by Kuwabara et al","volume":"81","author":"Rios Rodriguez","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0305","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0310","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: a systematic review","volume":"43","author":"Silva-Fern\u00e1ndez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0315","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2023.103362_bb0320","doi-asserted-by":"crossref","DOI":"10.2196\/16664","volume":"9","author":"Merkel","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.autrev.2023.103362_bb0325","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2020-eular.1073","article-title":"op0011\u00a0a randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis","volume":"79","author":"Merkel","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0330","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibod 2013; associated vasculitis","volume":"7","author":"van Leeuwen","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2023.103362_bb0335","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2023.103362_bb0340","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.berh.2009.03.001","article-title":"The diagnosis of vasculitis","volume":"23","author":"Jayne","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0345","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0350","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0355","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0360","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0365","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2023.103362_bb0370","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0375","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0380","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0385","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2023.103362_bb0390","doi-asserted-by":"crossref","first-page":"i123","DOI":"10.1093\/ndt\/gfv076","article-title":"Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2023.103362_bb0395","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0400","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0405","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000503318","article-title":"Sequential therapy for remission induction in severe antineutrophil cytoplasmic autoantibody-associated glomerulonephritis","volume":"50","author":"Kant","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2023.103362_bb0410","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0415","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0420","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0425","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.autrev.2015.05.013","article-title":"Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review","volume":"14","author":"Visentini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103362_bb0430","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10067-017-3552-6","article-title":"Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis","volume":"36","author":"Colantuono","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0435","article-title":"Treatment for hepatitis C virus-associated mixed cryoglobulinaemia","volume":"5","author":"Montero","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2023.103362_bb0440","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2023.103362_bb0445","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0450","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.autrev.2023.103362_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis c virus-associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0460","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis c virus-associated cryoglobulinemia vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0465","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2023.103362_bb0470","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820942617","article-title":"Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals","volume":"13","author":"Comarmond","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2023.103362_bb0475","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0480","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","article-title":"Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome","volume":"18","author":"Galli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103362_bb0485","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm."},{"key":"10.1016\/j.autrev.2023.103362_bb0490","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/kez311","article-title":"The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"59","author":"Shimizu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0495","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0500","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.39472","article-title":"Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: A French Nationwide Study of Ninety-Two Patients","volume":"68","author":"Crickx","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0505","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1002\/art.39858","article-title":"Intravenous immunoglobulin in antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Crickx et al","volume":"68","author":"Tamaki","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0510","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00296-017-3875-2","article-title":"Eosinophilic granulomatosis with polyangiitis complicated by subarachnoid hemorrhage and coronary vasculitis: a case report and review of the literature","volume":"38","author":"Matsuda","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103362_bb0515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.intimp.2017.01.025","article-title":"Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA)","volume":"45","author":"Pecoraro","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2023.103362_bb0520","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00415-014-7618-y","article-title":"Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial","volume":"262","author":"Koike","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2023.103362_bb0525","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10067-017-3752-0","article-title":"Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review","volume":"36","author":"Sakai","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0530","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/14397595.2016.1160968","article-title":"Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial","volume":"26","author":"Sakai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0535","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/TCRM.S159949","article-title":"Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy","volume":"14","author":"Faverio","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.autrev.2023.103362_bb0540","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4168\/aair.2020.12.5.885","article-title":"Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis","volume":"12","author":"Vultaggio","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.autrev.2023.103362_bb0545","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0550","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103362_bb0555","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2169\/internalmedicine.54.3668","article-title":"Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late?","volume":"54","author":"Ramirez","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0560","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12185-013-1323-y","article-title":"Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review","volume":"97","author":"Besada","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2023.103362_bb0565","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.ajkd.2015.11.014","article-title":"Fatal Cryocrystalglobulinemia With Intravascular and Renal Tubular Crystalline Deposits","volume":"67","author":"DeLyria","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0570","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10067-018-04423-y","article-title":"The complexity of an overlap type resistant cryoglobulinemia: a case report and review of the literature","volume":"38","author":"Tocut","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0575","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0580","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0585","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","article-title":"Alemtuzumab for refractory primary systemic vasculitis\u2014a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103362_bb0590","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a european collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0595","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0600","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/ard.43.6.783","article-title":"Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Beh\u00e7et\u2019s syndrome","volume":"43","author":"Yazici","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0605","first-page":"10","article-title":"Old and New Challenges in Uveitis Associated with Beh\u00e7et\u2019s Disease","author":"Gueudry","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0610","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","article-title":"Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: A systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"48","author":"Leccese","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0615","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14712598.2017.1328496","article-title":"Management of severe complications in Beh\u00e7et\u2019s disease with TNF inhibitors","volume":"17","author":"Desbois","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2023.103362_bb0620","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","article-title":"French recommendations for the management of Beh\u00e7et\u2019s disease","volume":"16","author":"Kone-Paut","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0625","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0630","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2023.103362_bb0635","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome--a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0640","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0645","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103362_bb0650","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0655","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Beh\u00e7et\u2019s Disease: National Multicenter Study of 177 Cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0660","doi-asserted-by":"crossref","first-page":"1623847","DOI":"10.1155\/2019\/1623847","article-title":"Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study","volume":"2019","author":"Bitossi","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2023.103362_bb0665","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","article-title":"Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Beh\u00e7et disease: a 2-year follow-up study","volume":"25","author":"Keino","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2023.103362_bb0670","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1016\/j.autrev.2023.103362_bb0675","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2023.103362_bb0680","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.oftal.2014.03.016","article-title":"Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Beh\u00e7et\u2019 disease","volume":"90","author":"Ba\u00f1eros-Rojas","year":"2015","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.autrev.2023.103362_bb0685","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10384-018-0589-2","article-title":"Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Beh\u00e7et disease","volume":"62","author":"Umazume","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.autrev.2023.103362_bb0690","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11894-020-00759-1","article-title":"Update on the treatment of behcet\u2019s disease of the small bowel with biologic agents","volume":"22","author":"Park","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.autrev.2023.103362_bb0695","first-page":"171","article-title":"Mucosal healing at 14 weeks predicts better outcome in low-dose infliximab treatment for chinese patients with active intestinal behcet\u2019s disease","volume":"47","author":"Zou","year":"2017","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.autrev.2023.103362_bb0700","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","article-title":"Long-term outcomes and predictors of sustained response in patients with intestinal behcet\u2019s disease treated with infliximab","volume":"62","author":"Zou","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2023.103362_bb0705","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103362_bb0710","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: A multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103362_bb0715","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.autrev.2016.01.003","article-title":"Pulmonary artery aneurysms in Beh\u00e7et\u2019s disease treated with anti-TNF\u03b1: A case series and review of the literature","volume":"15","author":"Chan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103362_bb0720","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","article-title":"Pulmonary artery involvement in Beh\u00e7et\u2032s syndrome: Effects of anti-Tnf treatment","volume":"45","author":"Hamuryudan","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0725","first-page":"147","article-title":"Duration of anti-TNF treatment in vascular Beh\u00e7et\u2019s disease: better to prolong treatment?","volume":"36","author":"Atas","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0730","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of Anti-TNF\u03b1 in Severe and Refractory Neuro-Behcet Disease: An Observational Study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103362_bb0735","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/1346-8138.12203","article-title":"Case of neuro-Beh\u00e7et\u2019s disease successfully maintained a remission using infliximab for 2 years","volume":"40","author":"Kanemaru","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0740","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1179\/2045772314Y.0000000209","article-title":"Recurrent longitudinal extensive transverse myelitis in a neuro-Beh\u00e7et syndrome treated with infliximab","volume":"38","author":"Uyguno\u011flu","year":"2015","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.autrev.2023.103362_bb0745","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a four-year follow-up study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2023.103362_bb0750","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0755","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","article-title":"Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 121","key":"10.1016\/j.autrev.2023.103362_bb0760","first-page":"43","article-title":"Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Beh\u00e7et\u2019s disease without formation of antidrug antibodies","volume":"37","author":"Verboom","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.08.042","article-title":"Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease","volume":"13","author":"Tanida","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0770","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.dld.2018.10.024","article-title":"Real-world efficacy of adalimumab and infliximab for refractory intestinal Beh\u00e7et\u2019s disease","volume":"51","author":"Sugimura","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0775","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/14397595.2016.1174327","article-title":"Intestinal Beh\u00e7et\u2019s disease with pyoderma gangrenosum successfully treated with the combination therapy of adalimumab and glucocorticoids","volume":"28","author":"Kashiwado","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0780","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.reuma.2016.03.010","article-title":"Beh\u00e7et\u2019s disease with intestinal perforation: A case report","volume":"13","author":"Della Maggiora","year":"2017","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.autrev.2023.103362_bb0785","article-title":"Successful closure of ileostomy in a patient with intestinal Beh\u00e7et\u2019s disease after therapy with adalimumab: A case report","volume":"98","author":"Yan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103362_bb0790","first-page":"367","article-title":"Severe neuro-Behcet\u2019s disease treated with a combination of immunosuppressives and a TNF-inhibitor","volume":"41","author":"Korkmaz","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.autrev.2023.103362_bb0795","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00296-013-2693-4","article-title":"Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Beh\u00e7et\u2019s disease","volume":"34","author":"Aamar","year":"2014","journal-title":"Rheumatol Int"},{"issue":"Suppl. 121","key":"10.1016\/j.autrev.2023.103362_bb0800","first-page":"3","article-title":"One year in review 2019: Beh\u00e7et\u2019s syndrome","volume":"37","author":"Hatemi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0805","first-page":"S54","article-title":"Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab","volume":"29","author":"Olivieri","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0810","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0815","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00393-013-1307-6","article-title":"Etanercept therapy in Beh\u00e7et\u2019s disease. The tight control strategy in refractory disease","volume":"73","author":"Mohammed","year":"2014","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0820","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","article-title":"Etanercept in the treatment of intestinal Behcet\u2019s disease","volume":"69","author":"Ma","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.autrev.2023.103362_bb0825","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5009\/gnl17462","article-title":"Anti-tumor necrosis factor therapy in intestinal Beh\u00e7et\u2019s disease","volume":"12","author":"Park","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.autrev.2023.103362_bb0830","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5414\/CN109262","article-title":"Beh\u00e7et\u2019s syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercept","volume":"89","author":"Leonard","year":"2018","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.autrev.2023.103362_bb0835","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et\u2019s disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.autrev.2023.103362_bb0840","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0845","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0850","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","article-title":"Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0855","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","article-title":"Certolizumab Pegol treatment in Behcet\u2019s disease with different organ involvement: A multicenter retrospective observational study","volume":"27","author":"Lopalco","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0860","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2022-eular.3331","article-title":"Pos1351 certolizumab pegol vs adalimumab in the treatment of refractory cystoid macular edema due to Beh\u00e7et\u2019s disease. Multicenter study","volume":"81","author":"Mart\u00edn-Varillas","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0865","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103362_bb0870","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0875","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurol.2017.02.006","article-title":"Efficacy and safety of tocilizumab in neuro-Beh\u00e7et\u2019s disease: A case report","volume":"173","author":"Essaadouni","year":"2017","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.autrev.2023.103362_bb0880","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl. 108","key":"10.1016\/j.autrev.2023.103362_bb0885","first-page":"116","article-title":"A case of refractory intestinal Beh\u00e7et\u2019s disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody","volume":"35","author":"Chen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0890","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet\u2019s disease: Four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0895","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0900","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","article-title":"Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u2032s disease","volume":"46","author":"Emmi","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103362_bb0905","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0910","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103362_bb0920","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0925","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00296-019-04259-y","article-title":"The right place of interleukin-1 inhibitors in the treatment of Beh\u00e7et\u2019s syndrome: a systematic review","volume":"39","author":"Bettiol","year":"2019","journal-title":"Rheumatol Int"},{"issue":"Suppl. 108","key":"10.1016\/j.autrev.2023.103362_bb0930","first-page":"130","article-title":"Ustekinumab efficacy and safety in mucocutaneous multi-refractory Beh\u00e7et\u2019s disease","volume":"35","author":"Lopalco","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0935","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/1756-185X.12680","article-title":"Interleukin-1 blockade in neuro-Beh\u00e7et\u2019s disease: a case-based reflection","volume":"20","author":"Vitale","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0940","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et\u2019s disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103362_bb0945","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0950","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology."},{"key":"10.1016\/j.autrev.2023.103362_bb0955","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: a multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0960","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","article-title":"Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et\u2019s syndrome: A preliminary study","volume":"97","author":"Di Scala","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103362_bb0965","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2016.03.020","article-title":"Neuro-Beh\u00e7et\u2019s disease presenting with tumour-like lesions and responding to rituximab","volume":"32","author":"Jade","year":"2016","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2023.103362_bb0970","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","article-title":"Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et\u2019s syndrome","volume":"262","author":"Kidd","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2023.103362_bb0975","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204366","article-title":"Treatment of myelitis in Beh\u00e7et\u2019s disease with rituximab","volume":"2014","author":"Messina","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2023.103362_bb0980","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb0985","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10067-013-2433-x","article-title":"Improved clinical control of a challenging case of Beh\u00e7et\u2019s disease with rituximab therapy","volume":"33","author":"Zhao","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103362_bb0990","first-page":"238","article-title":"Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet\u2019s Disease with Different Organ Involvement: A Case Series","volume":"18","author":"Cantarini","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2023.103362_bb0995","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103362_bb1000","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219810","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome\u2019","volume":"82","author":"Zou","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:29:33Z","timestamp":1761600573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":200,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1568997223000964"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103362","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapy in large and small vessels vasculitis, and Beh\u00e7et\u2019s disease: Evidence- and practice-based guidance","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103362"}}